MSN Formulation Facility receives PICS approval (12 Mar 2014)
We are happy inform that the Formulations facility of MSN Laboratories has been certified by PIC/S.
This certification has given us an opportunity to serve people across 44 more countries with state-of-the-art medicines at affordable prices.
MSN successfully completes the audit from FMHACA of Ethiopia. (30 Dec 2013)
The Formulation Division of MSN Laboratories Private Limited successfully completed the audit from Ethiopia on 29 Dec 2013.
MSN labs to invest Rs.150 cr for API, formulations & CRAMS unit in Hyderabad
MSN Laboratories Ltd, a fast growing active pharmaceutical ingredients and formulations company of India is planning to invest Rs.150 crore for setting up an API, formulations and CRAMS (Contract Research and Manufacturing Services) unit in Hyderabad
Started small with a single unit in the year 2003, today the Hyderabad based MSN Group has established 8 units across India of which 6 are manufacturing units catering to APIs, 1 unit for formulations and 1 research and development centre. Out of the 6 manufacturing units 3 units are US FDA certified while the remaining 3 are catering to ROW (Rest of the World) and Indian markets
Please click for more details
CPhI India Pharma Award 2012
MSN Laboratories Limited has been awarded CPhI India Award 2012 for "Innovation in Cost". It recognizes our contribution (1st-in-India generics of Bosentan, Lacosamide, Silodosin, etc. at very affordable prices) to Healthcare in India.
MSN Laboratories successfully completes USFDA audit for the 3rd successive time
Hyderabad based MSN Laboratories has successfully completed US FDA Audit. The group has 55 DMFs for the US market. Out of which 29 DMFs are from this facility.
Commenting on the development, Dr MSN Reddy, chairman & managing director, MSN Group, said, that the 3rd consecutive audit that has been successfully completed by the MSN Group. Achieving this for the 2nd time for the same unit has reiterated our belief and commitment towards quality.
Please click for more details
MSN Labs wins the FAPCCI Outstanding Export Performance Award
Pharmexcil's Outstanding Export Performance Awards
The Outstanding Export Performance Awards and Patent Awards for 2009-10, instituted by the Pharmaceuticals Export Promotion Council (Pharmexcil), were presented to leading pharma companies in a ceremony organized by the Pharmaexcil, as part of Pharma CEOs conclave in Hyderabad last week.
Twelve pharma majors have bagged the Outstanding Export Performance Awards-2009-10 and 24 companies have won Patent Awards for the same year.
The awards were presented by the Chief Minister of Andhra Pradesh, K Rosaiah. Giving away the awards, he said that his government has launched investor friendly industrial policy in the state giving major thrust for pharma and biotechnology sectors.
MSN Laboratories Awarded Emerging India SME 2010
We were awarded the Emerging India SME Award 2010 by ICICI/CRISIL/CNBC_TV18 in Macau (Hongkong) on 10th November 2010.
MSN Laboratories: A master in the making
In less than a decade, MSN Laboratories has consolidated its place as one of the fast growing pharma companies in India. Sachin Jagdale analyses the growth trajectory of the company It has barely been a decade since MSN Laboratories' inception, but the company's achievements would make even the industry veterans give them a standing ovation.
It is never an easy thing to start your own company, and to survive the grueling competition, is even more difficult; but when has a smooth sea made a good mariner: MSN Reddy, Chairman and Managing Director, MSN Laboratories, strongly believes in this philosophy.
MSN Group is one of the fastest growing manufacturers of active pharmaceutical ingredients (APIs) and finished dosages in India. Established in the year 2003, MSN group comprises four API manufacturing plants, one finished dosage facility and a dedicated technology development centre.
MSN Labs A master in the making
MSN Laboratories to set up a new R&D centre in Hyderabad
Hyderabad-based Rs 390 crore formulation and contract research and manufacturing services provider, MSN Laboratories, is setting up a new R&D centre in Hyderabad with an investment of over Rs 40 crore.
The full fledge commercial operation from the new centre will begin by first quarter of 2011. The company has arranged for funds from internal accruals.
New R&D centre in Hyderabad
MSN to make generic of blockbuster heart drug
Hyderabad Based MSN Laboratories has become the first company in India to receive permission to manufacture Prasugrel, the first generic in the world for Efient.
Efient is a blood thinner, which has been launched by Daiichi Sankyo in association with Eli Lily. The drug is expected to be a blockbuster. The former sees sales of more than 500 million through annual sales of the drug in Europe.
Excellence Performance Award in Research & Development for the year 2008-2009
We are happy to inform you that we were awarded the Excellence Performance Award in Research & Development (from FAPCCI)) by the Hon'ble Chief Minister,Govt.of Andhra Pradesh Mr. K. Rosaiah on 5.April.2009 at Hyderabad.MSN Award Photo
MSN Labs setting up R&D unit in Hyderabad
Hyderabad based MSN Laboratories Limited has embarked upon a Rs 150 crore expansion plan to be executed over a period of three years. The expansion programme includes setting up a research and development (R&D) center at Pashamylaram, near here, and construction of a formulation facility at the special economic zone near Jadcherla in Mahabubnagar district.Business Standard
Outstanding Export Performance Award for the year 2008-2009
We are happy to inform you that we were awarded the 'Outstanding Export Performance Award' (from Pharmexcil) by the Honorable Minister of Commerce Mr Anand Sharma in the presence of Chief Minister of A.P and Dr Surinder Singh, DCGI on 25.Sep.2009 at Hyderabad
MSN Successfully completes USFDA, EUGMP Audits
The Hyderabad-based MSN Laboratories Limited, the flagship company of the Rs 150 crore MSN Group of Companies, has successfully completed US FDA and EU GMP audits.
Commenting on the development, Dr M S N Reddy, chairman and managing director, MSN Laboratories, said, "It is a major achievement for us. We have achieved successful recognitions and approvals within a short span of four years of operations. Crossing this audit process has reiterated our belief in quality management and continuous process of innovation. It would help us in making a foray into the US and other regulated markets in the coming years."
Please click for more details
Brickwork Ratings has assigned BWR A to MSN Laboratories
Bangalore: 61% increase in FY-2007. As of 31st January 2009, MSN Labs has achieved 49% increase in PAT.
MSNL s key financial ratios are favorable and improving. In FY 2008, MSNL s debt equity ratio was just 0.71 and even as of 31st Jan 2009 it is about 0.40. Company s debt service coverage ratio improved from 0.25 in FY 2007 to 1.42 in FY2008, to 1.71 as of 31st Jan 2009. Interest coverage ratio improved to 5.64 as of 31st Jan 2009 from 3.86 in FY 2008. Net worth improved to INR 167.69 Million in FY 2008 from INR 102.89 Million in FY 2007, and further improved to INR 256.55 Million as of 31st Jan 2009.
MSN Labs gets EU certification
MSN Laboratories Pvt Ltd has received food manufacturing practice (GMP) certification from the European Union for its active pharmaceutical ingredient manufacturing facility at Pashmylaram near here. The Hyderabad-based company had its first inspection of GMP certification by the EU regulatory body in April, according to a release.
MSN Labs opens Bollarum formulations facility
MSN Laboratories Limited, part of the Hyderabad-based MSN Group, has inaugurated its formulation facility at Bollarum near Hyderabad.
MSN group acquires Armour Pharmaceuticals
Hyderabad based pharmaceutical ingredients manufacturer, MSN group, has acquired Armour Pharmaceuticals Ltd, a city based pharmaceutical formulations unit. The total project cost is Rs 11 crore, according to sources with the MSN group. This includes Rs 4.5 crore for the acquisition. An amount of Rs six core will be spent to revamp Armour. "We are currently active in API segment. This acquisition would scale up our business models and help us to move up our bottom line growth," sources said.